GeneDx Holdings Corp.
WGS
$70.69
-$4.81-6.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.81% | 49.44% | 50.26% | 52.07% | 54.43% |
| Total Other Revenue | 238.54% | 119.32% | -13.79% | -52.01% | -52.36% |
| Total Revenue | 39.97% | 50.50% | 48.70% | 48.81% | 50.79% |
| Cost of Revenue | 16.54% | 12.80% | 9.90% | 3.71% | -2.15% |
| Gross Profit | 53.34% | 76.17% | 79.69% | 93.63% | 118.16% |
| SG&A Expenses | 38.36% | 27.89% | 14.09% | 5.16% | -10.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.66% | 23.67% | 11.37% | 1.34% | -9.96% |
| Operating Income | 49.60% | 119.95% | 107.08% | 88.04% | 85.74% |
| Income Before Tax | 59.84% | 102.98% | 101.30% | 71.75% | 70.21% |
| Income Tax Expenses | 66.18% | 158.08% | 115.20% | 121.60% | 62.96% |
| Earnings from Continuing Operations | 59.80% | 102.49% | 101.20% | 71.43% | 70.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.80% | 102.49% | 101.20% | 71.43% | 70.25% |
| EBIT | 49.60% | 119.95% | 107.08% | 88.04% | 85.74% |
| EBITDA | 700.76% | 239.39% | 158.40% | 108.83% | 98.31% |
| EPS Basic | 63.35% | 102.42% | 100.78% | 72.58% | 73.59% |
| Normalized Basic EPS | 65.30% | 123.46% | 113.88% | 79.37% | 78.21% |
| EPS Diluted | 62.51% | 101.84% | 100.37% | 72.51% | 73.54% |
| Normalized Diluted EPS | 64.26% | 122.90% | 113.46% | 79.37% | 78.21% |
| Average Basic Shares Outstanding | 6.52% | 7.21% | 6.92% | 6.26% | 10.67% |
| Average Diluted Shares Outstanding | 7.61% | 8.32% | 8.04% | 6.26% | 10.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |